Stock MEDGENICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Press Releases Medgenics, Inc. Nyse

Equities

US58436Q2030

End-of-day quote Nyse
Other stock markets
- USD - Intraday chart for Medgenics, Inc.
2020 Aevi Genomic Medicine, LLC(NasdaqGM:GNMX) dropped from S&P TMI Index CI
2020 Aevi Genomic Medicine, Inc. Announces Resignation of Directors CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AEVI GENOMIC MEDICINE, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
AEVI GENOMIC MEDICINE, INC. : Unregistered Sale of Equity Securities, Regulation FD Disclosure, Other Events (form 8-K)
AQ
AEVI GENOMIC MEDICINE : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K/A)
AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
AQ
AEVI GENOMIC MEDICINE, INC. : Other Events (form 8-K)
AQ
AEVI GENOMIC MEDICINE, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
Aevi Genomic Medicine, Inc. : Receives Positive Nasdaq Listing Determination
PR
Aevi Genomic Medicine : Enters into License Agreement with AstraZeneca for Anti-IL-18 Antibody
PR
Aevi Genomic Medicine : to Present at the 2019 Wedbush PacGrow Healthcare Conference
PR
Aevi Genomic Medicine : Enters into Worldwide License Agreement with Astellas to Develop and Commercialize a Novel Second Generation mTORC1/2 Inhibitor
PR
Aevi Genomic Medicine : Announces Top-Line Results from Placebo-Controlled ASCEND Trial (Parts A & B) of AEVI-001 in Children with ADHD
PR
Aevi Genomic Medicine : to Host KOL Breakfast to Discuss Diagnosis and Treatment Paradigms in ADHD
PR
Aevi Genomic Medicine : Reports Third Quarter 2018 Financial Results and Provides Business Update
PR
Aevi Genomic Medicine : Announces Completion of Enrollment for Part B of the ASCEND Trial
PR
Aevi Genomic Medicine : to Present at the H.C. Wainwright 20th Annual Global Investment Conference
PR
Aevi Genomic Medicine : Announces Capital Raise of $4.9M to Accelerate Part B of the ASCEND Trial
PR
Aevi Genomic Medicine : Announces Completion of Enrollment in Part A of Phase 2 ASCEND Trial in ADHD
PR
Aevi Genomic Medicine : Reports Second Quarter 2018 Financial Results and Provides Business Update
PR
Aevi Genomic Medicine, Inc. : Announces Novel Co-crystal Version of AEVI-001
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. Stock
  5. News Medgenics, Inc.
  6. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW